Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease prostate cancer
Symptom C0030193|pain
Sentences 26
PubMedID- 24209520 Re: impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the tropic trial.
PubMedID- 26165617 Acute onset of headache or ocular pain in patients with metastatic prostate cancer warrants further workup to rule out orbital and intracranial metastases, rare but significant clinical entities that can lead to severe complications.
PubMedID- 24069538 Bone-seeking radiopharmaceuticals have historically been available but relegated as a palliative treatment for pain in patients with metastatic prostate cancer .
PubMedID- 21936635 Dimethyl sulfoxide-sodium bicarbonate infusion for palliative care and pain relief in patients with metastatic prostate cancer.
PubMedID- 23723295 Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the tropic trial.
PubMedID- 26242893 Methods: four hundred seventy prostate cancer patients with metastatic bone pain who were suitable for local radiotherapy were randomly assigned to radiotherapy (single dose, 8 gy) or intravenous infusion of ibandronate (6mg) in a noninferiority trial.
PubMedID- 21056263 Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
PubMedID- 24392443 In our study, the pain score (vas) in patients with advanced-stage prostate cancer was significantly higher than that in patients with early-stage prostate cancer.
PubMedID- 25469306 Therefore, sr-89 treatment was found to be effective in ameliorating bone pain associated with metastasis from prostate cancer.
PubMedID- 22557710 9 the presence of pain in men with advanced prostate cancer is an immediate indication for aggressive management with analgesics, while adequate treatments that address directly the cause of the pain are pursued.
PubMedID- 22502790 Background: tamoxifen (tam) has been shown to be active against the bicalutamide-induced breast events (bes) gynecomastia, and breast pain in patients with prostate cancer (pc).
PubMedID- 26064237 Together, these data suggest that atrasentan has an effect on cancer-related bone pain and skeletal-events in patients with prostate cancer.
PubMedID- 23443341 We discuss risk factors and diagnostic clues in this differential diagnosis of acute hip pain in patients with castration-resistant prostate cancer.
PubMedID- 23918298 An improved understanding of the neurobiology of pcibp has the potential to identify new targets for use in drug discovery programs aimed at producing a new generation of analgesics and/or adjuvant drugs for the improved relief of intractable pain due to advanced prostate cancer-induced bone pain.
PubMedID- 23144336 We tested the feasibility of using natural language processing (nlp) of text from clinical encounters to depict meaningfully the experience of pain in patients with metastatic prostate cancer over time.
PubMedID- 21103130 Perhaps the real indicators of the prostate adenocarcinoma in this case were the perineal symptoms while seated, as perineal pain sometimes occurs with prostate cancer,25 coupled with the overall increase in psa from 1.2 to 1.8 ng/ml over the 15-year period.
PubMedID- 23853055 Because guidelines suggest imaging for prostate cancer patients with bone pain (7) and 5.6% to 28.7% of men aged 50 to 80 years have back pain (29), the optimal rate of imaging should not be zero, even among men with low-risk features.
PubMedID- 22704706 Conclusions: our data have shown that both tmx and rt prevented gynecomastia and breast pain in patients with prostate cancer receiving adt for prostate cancer.
PubMedID- 24796851 3 reported a case of a 75-year-old male patient who was initially hospitalized with sacral pain was diagnosed with prostate cancer.
PubMedID- 22745584 Bone metastases have a devastating impact on quality of life and bone pain in patients with prostate cancer and decrease survival.
PubMedID- 20515602 Samarium-153 treatment of bone pain in patients with metastatic prostate cancer.
PubMedID- 23861996 Zoledronic acid is the only bisphosphonate that has statistically shown significant reductions in skeletal morbidity, including bone pain, in patients with metastatic prostate cancer .
PubMedID- 24127064 In this study, we examined the tumoricidal and pain-relief effects of sr-89 on prostate cancer with bone metastasis as well as survival.
PubMedID- 25859413 Palliative radiotherapy (prt) is primarily employed for palliation of bone pain in patients with castrate-resistant prostate cancer (crpc).
PubMedID- 22991663 Consequently, for the management of bone pain in patients with prostate cancer, we should consider altering the radiation dose or fraction using high-dose sbrt combining it with treatments such as systemic chemotherapy, zoledronic acid, and painkiller.
PubMedID- 26391636 Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: a systematic review.

Page: 1